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Abstract
Rubella is a viral infection that may cause fetal death or congenital defects, known as congenital 
rubella syndrome (CRS), during early pregnancy. The World Health Organization (WHO) 
recommends that countries assess the burden of rubella and CRS, including the determination of 
genotypes of circulating viruses. The goal of this study was to identify the genotypes of rubella 
viruses in the Democratic Republic of the Congo (DRC). Serum or throat swab samples were 
collected through the measles surveillance system. Sera that tested negative for measles IgM 
antibody were tested for rubella IgM antibody. Serum collected within 4 days of rash onset and 
throat swabs were screened by real-time RT-PCR for rubella virus RNA. For positive samples, an 
amplicon of the E1 glycoprotein gene was amplified by RT-PCR and sequenced. 11733 sera were 
tested for rubella IgM and 2816 (24%) were positive; 145 (5%) were tested for the presence of 
rubella RNA by real-time RT-PCR and 10 (7%) were positive. Seventeen throat swabs were 
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analyzed by RT-PCR and three were positive. Sequences were obtained from eight of the positive 
samples. Phylogenetic analysis showed that the DRC rubella viruses belonged to genotypes 1B, 
1E, 1G, and 2B. This report provides the first information on the genotypes of rubella virus 
circulating in the DRC. These data contribute to a better understanding of rubella burden and the 
dynamics of rubella virus circulation in Africa. Efforts to establish rubella surveillance in the DRC 
are needed to support rubella elimination in Africa.
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INTRODUCTION
Rubella is a contagious infection caused by rubella virus that occurs usually in children and 
young adults. This illness has serious consequences in pregnant women causing a variety of 
birth defects known as congenital rubella syndrome (CRS) [Reef et al., 2011]. Worldwide, 
an estimated 110,000 babies are born with CRS every year [WHO, 2012]. Rubella virus is 
the sole member of the Rubivirus genus in the Togaviridae family. The genome of rubella 
virus is a single-stranded positive sense RNA of approximately 10 kb. The genome encodes 
two non-structural proteins (P90 and P150) and three virion proteins: the capsid protein and 
two envelope glycoproteins E2 and E1. Although rubella is serologically monotypic, 
sequence analyses of the E1 glycoprotein showed that distinct genetic variants of rubella 
virus exist. Rubella virus is classified into two clades; Clade 1 is divided in 10 genotypes 
(1a, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 1I, and 1J) of which nine are recognized (uppercase letter) 
and one is provisional (lowercase letter). Clade 2 is divided in three genotypes (2A, 2B, and 
2C) [WHO, 2013]. The World Health Organization (WHO) standard sequence window for 
rubella genotyping is a 739 nucleotide (nt) region (nts 8731–9469) within the E1 
glycoprotein.
The WHO Measles and Rubella Laboratory Network has recommended the collection of 
rubella genotypic data to support the global control and elimination program [Centers-for-
Disease-Control-and-Prevention, 2005].
The Democratic Republic of Congo (DRC) is a developing country with a population of 73 
million (2012 estimate) living within an area of 2,345,000 km2 [CIA, 2012]. The national 
expanded program on immunization in the DRC includes the first dose of measles vaccine at 
9 months of age. Rubella vaccination has not been introduced in the vaccination schedule in 
the DRC and rubella-specific surveillance is not in place. As a consequence, information 
about rubella and CRS in the DRC is very limited. The WHO recommends that countries 
without rubella vaccination program assess the burden of rubella and CRS before starting a 
routine vaccination program [WHO, 2011]. In 2004, the DRC established measles case-
based surveillance following the WHO African Regional Office (WHO/AFRO) measles 
surveillance guidelines [WHO/AFRO, 2004]. The case definition for measles surveillance 
also captures some rubella cases. The surveillance program in support of measles 
elimination in the African region recommended that cases that tested negative or 
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indeterminate for measles IgM antibody be tested for rubella IgM antibody [WHO/AFRO, 
2004]. Virological surveillance data on rubella viruses are used to track progress towards the 
goal of rubella elimination, help with case classification, monitor transmission pathways, 
and identify interruption of transmission of endemic genotypes of the virus.
This article summarizes the results of rubella testing obtained through the measles case-
based surveillance system. The epidemiology of laboratory-confirmed rubella cases and 
genotyping of rubella virus strains identified in the DRC from 2004 to 2013 are described.
MATERIALS AND METHODS
Sample Collection
All samples were collected in the DRC as part of routine measles surveillance from 2004 to 
2013. Serum samples were collected from patients who met the measles case definition, 
using the WHO/AFRO guideline for measles surveillance [WHO/AFRO, 2004]. Throat 
swabs samples were collected when possible from the same patients. A suspected measles 
case was defined as any person with generalized maculopapular rash and fever plus one of 
the following: cough, coryza or conjunctivitis, or any person in whom a clinician suspects 
measles.
Enzyme-Linked Immune-Sorbent Assay (ELISA)
All samples were sent to the national reference laboratory at the Institut National de 
Recherches Biomedical (INRB) for laboratory testing. All samples were first screened for 
measles IgM antibody by ELISA using a commercial kit, Enzygnost® anti-measles virus 
IgM (Siemens, Marburg, Germany). Samples that were determined to be measles IgM 
negative or indeterminate were tested for rubella IgM antibody using the Enzygnost® anti-
rubella virus IgM kit (Siemens). Patients with rubella IgM positive samples were classified 
as laboratory confirmed rubella cases.
Laboratory Molecular Testing of Rubella Samples
Screening of rubella IgM positive serum and throat swabs from cases that were also IgM 
positive by serology, collected between 2006 and 2013 was undertaken using the RT-PCR 
technique to detect rubella virus RNA as described in Namuwulya et al. [2014]. Briefly, the 
end point RT-PCR was performed using the Qiagen One-Step RT-PCR kit (Qiagen, Valencia, 
CA) and one forward and two reverse primers that amplify a 185-bp region in the rubella E1 
protein coding region. All RT-PCR positive samples and all samples positive for rubella IgM 
by ELISA tests were sent to the Centers for Disease Control and Prevention (CDC) in 
Atlanta, USA, for sequencing and genotyping. At the CDC, blood derived samples were 
used for further testing if they were collected less than four days from symptom onset, or if 
the date of collection was unknown, since previous work showed that blood samples 
collected later than three days after onset were unlikely to be positive [Zheng et al., 2013].
RNA Extraction and FTA Cards
Serum and throat samples, 200 μl of each, were either directly added on 1/4 inch punches 
from an FTA card (Capitol Scientific, Austin, TX) for transportation purposes or RNA was 
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first extracted from 140 μl of the serum/throat swab specimens using the QiaAmp Viral RNA 
Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Thirty 
microliters of RNA was then added on 1/4 inch punches from an FTA card and at the CDC 
re-extracted from FTA card using the QiaAmp Viral Mini Kit according to the 
manufacturer’s instructions with the following modifications. The punches were placed in 
1.5 μl microfuge tubes containing 600 μl of the kit lysis buffer, the recommended amount of 
carrier RNA, and 150 μl of PBS. The tubes were vortexed, incubated at room temperature 
for 10 min, and spun at 13000 rpm for 2 min. After removal of 700 μl to a new tube, the rest 
of the extraction was carried out according to the manufacturer’s instructions, with a final 
elution volume of 60 μl. For laboratory negative controls, RNA was extracted from 140 μl of 
transport media for the throat swabs and blank FTA card punches for the blood/serum spots.
Real-Time RT-PCR and Nested-Set Amplifications
A real-time RT-PCR assay, which was used to detect the presence of rubella virus RNA in 
serum (145) and throat swab(17) samples using the Invitrogen Superscript III Platinum qRT-
PCR kit (Invitrogen, Carlsbad, CA), amplified a 185 nucleotide (nt) fragment of the E1 
coding region as previously described [Abernathy et al., 2009]. The assay was modified by 
the addition of a second reverse primer (RV12-2: CCACGAGCCGCGAACAGTCG), which 
enhanced detection of Clade 2 rubella viruses by changing three of the nucleotides in the 
primer sequence to match the Clade 2 consensus sequence for the region. All throat swab 
RNAs were tested, but RNAs from blood spots were screened by real-time RT-PCR only if 
they were collected within three days of the onset of symptoms. RNA samples that were 
positive by real-time RT-PCR were used as templates in one or more of four nested RT-PCR 
assays using specific primers pairs (Table I). The nested RT-PCR assays were designed to 
amplify regions of the RV E1 coding region which encompassed the 739-nt region 
recommended by WHO for rubella genotyping. Samples with low Cts (30–34) on real time 
PCR analyses were sequenced using templates amplified by the 739-nt nested RT-PCR. 
Those with higher Cts (>35), required a pair of nested sets of primers as follows: (i) the 601-
nt set and the 138-nt Clade 1 set for the 1B and 1G sequence and (ii) the 601-nt and 138-nt 
Clade 2 set for the 2B sequences.
All nested RT-PCR assays were performed with the Superscript III One-Step Platinum Taq 
HiFi kit (Invitrogen Carlsbad, CA) modified by the addition of betaine to a final 
concentration of 1M (Sigma, St. Louis, MO) and using 2.5 μl of extracted RNA as the first 
round template in a total reaction volume of 25 μl. Cycling conditions for round one 
consisted of 30 min at 55°C, 2 min at 94°C and 40 cycles of 10 sec at 94°C, 15 sec at 55°C, 
and 1 min at 68 °C. For the second round, 1 μl of the first round PCR was transferred to the 
second round reaction tube and the 30 min at 55°C RT phase was eliminated. Negative and 
positive controls were carried through both rounds and strict segregation of master mix 
preparation and template addition was followed.
Sequencing and Phylogenetic Analysis
DNAs from nested RT-PCR positive reactions were purified using the Charge Switch PCR 
Clean-Up kit (Invitrogen Carlsbad, CA). The 739 nt sequences of the standard window used 
for genotyping RVs were determined bi-directionally using Applied Biosystems Prism 
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BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster 
City, CA) and a 3130 DNA sequencer (Applied Biosystems). Assembly of sequences was 
performed with Sequencher V5.2.3 (Gene Codes, Ann Arbor, MI). Genotype assignments 
were made using an alignment of sequences from the DRC and the 32 WHO reference virus 
sequences [WHO, 2013] using the neighbor joining algorithm of the MEGA6 program 
[Tamura et al., 2013]. Rubella sequences from the neighboring countries of Sudan [Omer et 
al., 2010], Uganda [Namuwulya et al., 2014], and Tanzania [Centers-for-Disease-Control-
and-Prevention, 2013] were also used in this analysis. Rubella sequences from this study 
were deposited on GenBank under accession numbers KU218397-KU218404.
RESULTS
Epidemiology of Rubella Infection in the DRC
From 2004 to 2013, 12,255 serum samples collected through the measles surveillance 
system were found negative or indeterminate for measles infection after measles IgM testing 
in the laboratory in the DRC. Of these serum samples, 11,733 were analyzed for the 
presence of rubella IgM and 522 were not analyzed. Of these 11,733 samples, 2,816 (24%) 
were positive for rubella IgM, 8,447 were negative, and 470 had indeterminate results for 
rubella IgM (Table II). The number of rubella IgM positive cases increased from 73 in 2004 
to 766 in 2013. The percentage of rubella IgM positive cases varied from 13% in 2005 to 
46% in 2013 (Table II).
Geographic and Age Distribution of Rubella Infection
Geographic origin was identified for all but two samples. Rubella cases were identified from 
all eleven provinces of the country with the highest positivity rate found in Bandudu 
province (43%) followed by Bas-Congo (41%), Kinshasa (33%), and Nord-Kivu (25%) 
(Table III). Of the 2,816 confirmed rubella case-patients, 2,794 (99%) had information on 
age. The age distribution of confirmed rubella cases ranged from 1 month to 49 years. Mean 
age was 21.6 years and median age was 24.5 years. The majority of rubella cases was 
concentrated in the group of children aged 5–9 years (43%) followed by age 1–4 years 
(31%) and 10–14 years (16%). Five percent (5%) were 15 years of age or older and 4% were 
less than 1 year (Fig. 1). Among rubella positive cases, gender information was available for 
2,789 (99%) of which 1,409 (50.5%) were male and 1,380 (49.5%) were female. Eighty-one 
rubella cases (3%) were among women of reproductive age (15–49 years).
Rubella Virus Genotypes and Their Geographic Locations
To characterize the virus, RNA samples were first analyzed by real-time PCR to identify the 
viral RNA. There were no samples available for PCR testing between 2004 and 2005. Of 
162 samples (17 were from throat swabs and 145 were from rubella IgM positive serum) 
analyzed by real-time PCR, 13 samples including 10 serum and three throat swabs samples 
were positive. Of those, the 739nt window of the E1 glycoprotein gene could be amplified 
for eight samples and the PCR products were sequenced. Phylogenetic analysis showed that 
the DRC rubella viruses belonged to genotypes 1B, 1E, 1G (1 sample each), and 2B (5 
samples) (Fig. 2). Genotype 1E was detected in 2007, genotype 1B in 2008, genotype 1G in 
2011, and genotype 2B in 2012 and 2013.
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Geographic location of rubella strains showed that three different genotypes were found in 
Kinshasa province; genotype 1B (RVs Kinshasa.COD 25.08), genotype 1E (RVs 
Kinshasa.COD 51.07), and genotype 2B (RVs Kinshasa.COD 42.12, Rvs Kinshasa. COD 
23.12, and Rvs Kinshasa.COD 24.12). Genotype 2B was also found in Banbundu (RVs 
Kimbau.COD 33.12) and Equateur (RVs Zongo.COD.13.13) provinces, while genotype 1G 
was found in Sud Kivu (RVs SudKivu.COD 1.11) province (Fig. 3).
DISCUSSION
This report provides the first information on the genotypes of rubella viruses found in the 
DRC. As of 2014, rubella vaccine was not introduced in the national immunization program 
and there was no rubella surveillance system in the DRC. The percentage of rubella 
confirmed cases in the DRC (24%) was similar to the rubella positivity rate (25%) 
previously found in African region during 2002–2009 [Goodson et al., 2011]. Both rates 
were derived from ELISA testing of measles surveillance samples that tested measles IgM 
negative. The majority of reported rubella cases during 2004–2013 occurred in persons older 
than 5 years (64%). These findings are similar to the results reported from a study of rubella 
cases in Uganda in 2003–2012 [Namuwulya et al., 2014]. Three percent (3%) of rubella 
cases occurred among women older than 15 years which corresponds to child bearing age in 
Africa, and therefore represents a risk for congenital rubella syndrome (CRS). This is 
slightly lower than the data recently reported on rubella in the African region where 5% of 
confirmed rubella cases were found among women of reproductive age [Goodson et al., 
2011]. It is noteworthy that this report is based only on samples collected for measles 
surveillance and thus may not represent the complete picture of rubella in the DRC.
Genomic characterization was performed on eight samples by amplification of a 739 
window of the E1 region as recommended by WHO guidelines [WHO, 2013]. Phylogenetic 
analysis identified rubella viruses of distinct genotypes circulating in the DRC between 2007 
and 2013: 1B, 1E, 1G, and 2B. Genotype 1B was found in 2008. This is the first report of 
this virus in the Central African region. This may be because only very few countries in 
Africa have studied the molecular biology of rubella viruses circulating in their country. 
Genotype 1E, found in the DRC in 2007 was previously identified in Sudan in 2005 [Omer 
et al., 2010] and more recently in Uganda in 2011 [Namuwulya et al., 2014]. Sequence 
analysis showed that the sequence of the DRC strain 1E differs from the 1E strain from 
Sudan and Uganda sequences by 3%. Genotype 1G was found in the DRC in 2011. This 
genotype is known to be prevalent in central Africa [WHO, 2007; Abernathy et al., 2011]. It 
was found in Uganda in 2003, 2011–2012 [Namuwulya et al., 2014], in Sudan in 2005 
[Omer et al., 2010] and more recently imported into the USA from Tanzania in 2012 
[Centers-for-Disease-Control-and-Prevention, 2013]. The genotype 1G sequence from the 
DRC differs from the Tanzanian strain by 1% and from Uganda’s sequences by 2%. It 
differs from the Sudan 2005 sequence by 3%. The 739nt of E1 gene sequence was identical 
between four of the genotype 2B viruses and one virus, RVs/Kinshasa.COD/42.12, varied by 
two nucleotides. This genotype was found in Sudan in 2006 [Omer et al., 2010]. Sequence 
comparison of the 224 nucleotides available in GenBank for Sudan 2006 with the DRC 
genotype 2B sequences showed that they differ by 4%.
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This study has some limitations. The low percentage of rubella RNA positive samples (8%) 
may be because that the analysis were performed on samples collected for the purpose of 
measles surveillance with unknown storage histories. The majority of the samples were 
derived from blood which has been shown to have a low positivity rate compared to 
respiratory samples even on days immediately after symptom onset. The low amount of 
rubella RNA present in blood derived samples likely also explains why the 739nt of the E1 
glycoprotein gene could be amplified from only eight samples [Abernathy et al., 2009; 
Zheng et al., 2013]. The origin of rubella viruses could not be traced due to the absence of a 
rubella surveillance system in the DRC. It is therefore not possible to say if these rubella 
strains are endemic or imported.
This report provides base line information on rubella epidemiology and genetic information 
on rubella strains circulating in the DRC. These data will help track endemic viruses and 
monitor the evolution of rubella virus once the rubella vaccine is introduced in the country. 
Furthermore, these data will contribute to a better understanding of the dynamics of rubella 
virus circulation in Africa. Efforts to establish rubella surveillance in the DRC and 
strengthen virologic surveillance of rubella viruses are needed in order to provide support to 
the rubella control in Africa.
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Fig. 1. 
Age and sex distribution of rubella-confirmed cases in DRC, 2004–2013.
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Fig. 2. 
Phylogenetic analysis of rubella virus strains found in the DRC (black circles). Rubella virus 
strains from neighboring countries are also indicated (black triangles). Remaining sequences 
are WHO reference sequences. Significant bootstrap values (>80%) are indicated.
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Fig. 3. 
Geographical location of rubella virus genotypes (in rectangles) found in the Democratic 
Republic of the Congo. Rubella genotypes found in neighboring countries are also indicated 
under the country’s name.
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TABLE I
Primer Sequences for Four Nested RT-PCR Assays
Primer name Primer sequence PCR product size Sequence region and clade specificity
RV8633F-1st round AGCGACGCGGCCTGCTGGGG 945 739-nt common to clade 1 and 2
RV9577R-1st round CGCCCAGGTCTGCCGGGTCTC
RV8669F-2nd round GTGATGAGCGTGTTCGCCCTT 873
RV9541R-2nd round GTGTGTGCCATACACCACGCC
RV11 (8812F)-1st round CAACACGCCGCACGGACAAC 766 601-nt fragment, common to clade 1 and 2
RV9577R-1rst round CGCCCAGGTCTGCCGGGTCTC
RV8823F-2nd round ACGGACAACTCGAGGTCC 727
RV9541R-2nd round GTGTGTGCCATACACCACGCC
RV8699F-1st round GTGATGAGCGTGTTCGCCCTT 328 138-nt fragment specific to clade 1
RV12 (8996R)-1st round CCACAAGCCGCGAGCAGTCA
RV8691-2nd rounda CTAGCTACGTCCAGCACCCT 271
RV8961R-2nd round CAAACCGGGGAGGCCCA
RV8669F-2B-1st round GTGATGAGCGTGTTCGCCCT 328 138-nt fragment specific to clade 2
RV12-2 (8996R)-1st round CCACGAGCCGCGAACAGTCG
RV8691F-2B-2nd round CTAGCTACGTCCAGCACCC 271
RV8961R-2nd round CAAACCGGGGAGGCCCA
aCooray et al. [2006].
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TABLE III
Distribution of Laboratory-Confirmed Rubella Cases by Provinces, DRC, 2004–2013
Province Measles IgM negative and 
indeterminate
Specimen tested for 
rubella IgM
Rubella IgM-positive cases Rubella positivity 
percentage (%)
Bas-Congo 689 634 257 41
Bandundu 648 608 264 43
Equateur 1,120 1,092 271 25
Katanga 3,000 2,902 589 20
Kinshasa 1,544 1,403 457 33
Kassai Occidental 780 743 164 22
Kasai Oriental 963 946 124 13
Maniema 419 398 55 14
Nord Kivu 603 585 148 25
Province Orientale 2,033 1,973 380 19
Sud Kivu 454 447 106 24
Unknown origin 2 2 1 50
Total 12,255 11,733 2,816 24
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